Japan Tissue Engineering Co., Ltd. (7774) AI Stock Analysis

• Market Cap: ¥26.11B
• Dividend Yield: N/A
• Average Volume (3M): 51.90K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.99
• Revenue Growth: -5.65%
• EPS Growth: -469.19%
• Country: JP
• Employees: 211
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -4.56
• Shares Outstanding: 40,610,200
• 10 Day Avg. Volume: 45,190
• 30 Day Avg. Volume: 51,896
• PEG Ratio: 0.26
• Price to Book (P/B): 3.19
• Price to Sales (P/S): 7.56
• P/FCF Ratio: -82.67
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 54 Neutral
• Price Target: ¥707.00 ▲(22.96% Upside)
• Action: Reiterated Date: 03/05/26
• Date: Action: Reiterated 03/05/26

The score is driven primarily by mixed financial performance: rapid revenue growth and a strong, low-debt balance sheet are offset by FY2025 losses and ongoing cash burn. Technically the stock is in an uptrend, but overbought signals temper the outlook. Valuation is also a drag due to negative earnings and no dividend yield.

Positive Factors

Very low debt / strong balance sheet

A near-zero debt profile provides durable financial flexibility for a capital-intensive biotech: it lowers bankruptcy risk, preserves headroom for clinical and commercial investments, and reduces refinancing pressure while the company pursues revenue scaling and product rollouts.

Rapid revenue growth

Strong, recurring top-line growth indicates improving commercial traction for approved cell therapy products and services. Persistent revenue expansion supports scale economies, capacity utilization, and the potential to convert gross-margin strength into sustainable operating profits if cost discipline follows.

Commercialized products plus CDMO services

Owning approved regenerative therapies while offering CDMO-like services creates diversified, structurally durable revenue streams. The combined product sales and service model leverages regulatory/compliance expertise and creates higher switching costs for customers, supporting repeat business.

Negative Factors

Negative operating and free cash flow

Persistent cash burn undermines self-funding capacity; ongoing negative operating and free cash flow raise the probability of external financing needs. That can dilute shareholders, impose funding timing risk for R&D/clinical programs, and constrain long-term scaling plans.

Return to losses in FY2025

Reverting from profitability to material losses signals execution or cost-control challenges. This volatility complicates multi-year planning, reduces retained-earnings capacity to fund growth, and increases reliance on external capital if profitability is not sustainably restored.

Operating costs pressure margins

High gross margins are offset by elevated operating expenses, suggesting fixed-cost intensity or inefficient overhead. Until operating leverage is realized, margin volatility will persist, slowing the translation of revenue gains into durable net income and free cash flow.

Japan Tissue Engineering Co., Ltd. Business Overview & Revenue Model

Company Description

Japan Tissue Engineering Co., Ltd. engages in the regenerative medicine business in Japan. The company operates through Regenerative Medicine Product, Regenerative Medicine Outsourcing, and Research and Development Support segments. It offers autologous cultured epidermis, cartilage, corneal epithelium, and oral mucosal epithelium to medical institutions for the purpose of medical treatment. The company also provides tissue-engineered medical products. In addition, it researches and develops human 3-dimensional cultured tissue models for use in the development of cosmetics and drugs for external use, as well as in research that employs skin and cornea tissues. Further, the company offers regenerative medicine contract development and manufacturing services. The company was founded in 1999 and is headquartered in Gamagori, Japan. Japan Tissue Engineering Co., Ltd. is a subsidiary of Teijin Limited.

How the Company Makes Money

J-TEC generates revenue through the sale of its tissue-engineered products, which are used in medical treatments and procedures. The company's primary revenue streams come from the commercial sales of its cultured tissue products to hospitals and medical institutions. Additionally, J-TEC is involved in collaborative research and development projects with academic institutions and other corporations, which may provide additional funding and revenue opportunities. The company also invests in intellectual property development and may earn income through licensing agreements or partnerships with other entities in the regenerative medicine space.

Japan Tissue Engineering Co., Ltd. Financial Statement Overview

Summary

Strong revenue growth and a very low-debt balance sheet are positives, but the profile is held back by a return to losses in FY2025 and recurring negative operating/free cash flow, indicating inconsistent profitability and self-funding capacity.

Income Statement

Revenue growth is a clear positive, with FY2025 revenue up ~81% year-over-year after FY2024 grew ~24%. Profitability, however, is inconsistent: FY2024 was profitable (about 5.7% net margin), but FY2025 slipped back to losses (about -10.4% net margin) and negative operating profit. Gross margin remains strong (roughly 56%–67% over recent years), but operating costs continue to pressure earnings and make results volatile.

Balance Sheet

The balance sheet is a major strength: debt is effectively zero and the company is financed primarily with equity (debt-to-equity ~0). Equity is sizeable relative to assets, supporting flexibility through down cycles. The key weakness is returns: return on equity turned negative in FY2025 after a positive FY2024, reflecting the swing back to losses rather than balance sheet leverage.

Cash Flow

Cash generation is a concern. Operating cash flow and free cash flow were negative in FY2025 (and also negative in multiple prior years), indicating the business is not yet consistently self-funding. FY2024 showed positive operating cash flow and near-breakeven free cash flow, but the rebound did not hold into FY2025, raising execution and funding-risk sensitivity despite the low-debt profile.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	2.44B	2.46B	2.51B	2.03B	2.10B	2.26B
Gross Profit	1.48B	1.51B	1.69B	1.14B	1.26B	1.16B
EBITDA	-74.19M	-76.02M	278.56M	-597.00M	-374.00M	-338.62M
Net Income	-286.87M	-255.30M	143.17M	-729.32M	-497.89M	-466.62M
Balance Sheet
Total Assets	6.29B	6.51B	6.99B	6.88B	7.60B	8.12B
Cash, Cash Equivalents and Short-Term Investments	3.92B	3.89B	4.27B	4.13B	4.93B	5.28B
Total Debt	0.00	0.00	0.00	133.00K	936.00K	1.74M
Total Liabilities	710.70M	687.95M	908.43M	946.15M	931.66M	954.78M
Stockholders Equity	5.58B	5.83B	6.08B	5.94B	6.67B	7.16B
Cash Flow
Free Cash Flow	0.00	-224.48M	938.00K	-798.60M	-342.48M	-473.98M
Operating Cash Flow	0.00	-148.37M	274.14M	-622.60M	-225.25M	-399.59M
Investing Cash Flow	0.00	-232.53M	-242.23M	1.12B	-116.48M	125.89M
Financing Cash Flow	0.00	-3.00K	-134.00K	-803.00K	-823.00K	-1.30M

Japan Tissue Engineering Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 575.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7774, the sentiment is Positive. The current price of 575 is below the 20-day moving average (MA) of 663.25, below the 50-day MA of 597.26, and above the 200-day MA of 550.05, indicating a bullish trend. The MACD of 47.67 indicates Negative momentum. The RSI at 60.04 is Neutral, neither overbought nor oversold. The STOCH value of 40.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:7774.

Japan Tissue Engineering Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4978	56 Neutral	¥16.87B	120.78	―	―	1.24%	-33.41%
7096	56 Neutral	¥8.58B	33.49	―	―	2.99%	-52.75%
7774	54 Neutral	¥26.11B	-34.16	―	―	-5.65%	-469.19%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
4593	50 Neutral	¥55.76B	-13.30	―	―	-82.33%	47.73%
7776	49 Neutral	¥12.62B	-8.14	―	―	-42.49%	-2.37%
4599	43 Neutral	¥18.18B	-8.15	―	―	―	11.34%

Japan Tissue Engineering Co., Ltd. Corporate Events

Japan Tissue Engineering Widens Loss and Cuts Sales Outlook for Fiscal 2025

Japan Tissue Engineering reported non-consolidated results for the nine months to 31 December 2025 showing an 11.5% year-on-year decline in net sales to ¥1.51 billion and a deeper operating loss of ¥563 million, with net loss widening to ¥556 million as earnings per share fell to negative ¥13.70. Total assets decreased to ¥5.89 billion and equity declined, though the equity ratio remained high at 89.4%, the company maintained a zero-dividend policy for the period and full year, and it revised its full-year forecast to project a 10% drop in sales to ¥2.21 billion and a continued net loss of ¥540 million, underscoring ongoing profitability challenges despite a still-solid capital base.

The most recent analyst rating on (JP:7774) stock is a Hold with a Yen578.00 price target. To see the full list of analyst forecasts on Japan Tissue Engineering Co., Ltd. stock, see the JP:7774 Stock Forecast page.

J-TEC Wins National Insurance Coverage for Expanded JACC Use in Knee Osteoarthritis

Japan Tissue Engineering announced that its autologous cultured cartilage product JACC will be newly covered by Japan’s national health insurance for an expanded indication that now includes knee osteoarthritis, effective January 1, 2026. JACC, already approved and reimbursed for traumatic cartilage defects and osteochondritis dissecans, becomes available as an insured regenerative treatment for patients whose knee osteoarthritis symptoms do not improve with conservative therapies and who have a defined minimum cartilage defect area, with reimbursement set at 1 million yen for the tissue transport set and 1.89 million yen for the cultured cartilage package. The broader insurance coverage is expected to increase patient access to advanced cartilage repair, strengthen J-TEC’s position in orthopedic regenerative medicine, and support the company’s strategy to expand its business while enhancing clinical outcomes and quality of life for an aging population with rising knee joint disorders.